So far the news points to continued good news. Personally that news yesterday is the most bullish thing I have read on NAVB, although I expect partnership and sNDA coming soon to trump it. Lilly dropped $800M into Amyvid which is based in PiB, which is what AIBL just walked away from and replaced with an unapproved imaging agent by NAVB still in trials, Point is that the researchers know the NAVB agent is better than the best even if the agencies haven't figured it out yet. :

http://finance.yahoo.com/news/study-navidea-a...45584.html